Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis

Journal of Clinical Laboratory Analysis

Volumn 21, Issue 3, 2007, Pages 193-196

  Tsao, Kuo Chien ^a   Hong, Ji Hong ^a   Wo, Tsu Lan ^a   Chang, Pi Yuen ^a   Sun, Chien Feng ^a   Wu, James T ^b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

Benign tumor; CA 125; CA 19 9; CgA; Endometriosis; Leiomyoma; Multiple tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; ANTIGEN DETECTION; ARTICLE; BRAIN TUMOR; CANCER RISK; CLINICAL ARTICLE; ENDOMETRIOSIS; FEMALE; HUMAN; IMMUNOASSAY; LEIOMYOMA; OVARY CARCINOMA; PATIENT MONITORING; TUMOR DIAGNOSIS;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; CHROMOGRANIN A; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; FEMALE; HUMANS; LEIOMYOMA; MASS SCREENING; TUMOR MARKERS, BIOLOGICAL;

EID: 34249287015     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20168     Document Type: Article

References (9)

1. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT. Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal 2006;20:42-46.
2. Brinton LA, Sakoda LC, Sherman ME, et al. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 2005;14:2929-2935.
3. Swiersz LM. Role of endometriosis in cancer and tumor development. Ann NY Acad Sci 2002;955:281-292.
4. Scarpellini F, Minozzi M, Curto C, Scarpellini L. CA-125 and uterine leiomyomas. Acta Eur Fertil 1993;24:75-76.
5. Hilger WS, Magrina JF. Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy. Obstet Gynecol 2006;108:772-774.
6. Wu TL, Chang CPY, Tsao KC, Sun CF, Wu JT. Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and the detection of elevated CgA in carcinomas. J Clin Lab Anal 1999;13:312-319.
7. Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998;13:231-237.
8. Wu JT, Wu T-L, Chang CP-Y, Tsao K-C, Sun C-F. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J Clin Lab Anal 1999;13:308-311.
9. Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF. Elevated serum CgA is detectable in carcinomas at advanced stage. Ann Clin Lab Sci 2000;30:175-178.